Search results for " HOMOLOGY MODELING"

showing 7 items of 7 documents

In Silico Conformational Features of Botulinum Toxins A1 and E1 According to Intraluminal Acidification

2022

International audience; Although botulinum neurotoxins (BoNTs) are among the most toxic compounds found in nature, their molecular mechanism of action is far from being elucidated. A key event is the conformational transition due to acidification of the interior of synaptic vesicles, leading to translocation of the BoNT catalytic domain into the neuronal cytosol. To investigate these conformational variations, homology modeling and atomistic simulations are combined to explore the internal dynamics of the sub-types BoNT/A1 (the most-used sub-type in medical applications) and BoNT/E1 (the most kinetically efficient sub-type). This first simulation study of di-chain BoNTs in closed and open s…

<i>Clostridium botulinum</i>; botulinum toxin; molecular dynamics; residue protonation; homology modeling[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry Molecular Biology/Structural Biology [q-bio.BM][SDV.BBM.BS] Life Sciences [q-bio]/Biochemistry Molecular Biology/Structural Biology [q-bio.BM]Health Toxicology and Mutagenesismolecular dynamichomology modelingresidue protonation[SDV.BBM.BP] Life Sciences [q-bio]/Biochemistry Molecular Biology/BiophysicsHydrogen-Ion ConcentrationToxicology[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologySettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)molecular dynamics[SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry Molecular Biology/BiophysicsGangliosidesSolventsClostridium botulinumbotulinum toxinBotulinum Toxins Type A[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM][INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]
researchProduct

Maintenance of a Protein Structure in the Dynamic Evolution of TIMPs over 600 Million Years

2016

Deciphering the events leading to protein evolution represents a challenge, especially for protein families showing complex evolutionary history. Among them, TIMPs represent an ancient eukaryotic protein family widely distributed in the animal kingdom. They are known to control the turnover of the extracellular matrix and are considered to arise early during metazoan evolution, arguably tuning essential features of tissue and epithelial organization. To probe the structure and molecular evolution of TIMPs within metazoans, we report the mining and structural characterization of a large data set of TIMPs over approximately 600 Myr. The TIMPs repertoire was explored starting from the Cnidaria…

Models Molecular0301 basic medicineTIMPsProtein familyProtein Conformationhomology modelingSettore BIO/11 - Biologia MolecolareSequence alignmentBiologytranscriptome wide analysisConserved sequencecnidariansEvolution MolecularCnidaria03 medical and health sciences0302 clinical medicineProtein structurePhylogeneticsMolecular evolutionGeneticsAnimalsTIMPAmino Acid SequenceHomology modelingcnidarianConserved SequencePhylogenyEcology Evolution Behavior and SystematicsGeneticsmyrTissue Inhibitor of Metalloproteinases030104 developmental biologyEvolutionary biologyTIMPs; cnidarians; homology modeling; transcriptome wide analysisSequence Alignment030217 neurology & neurosurgeryResearch Article
researchProduct

Homology models of melatonin receptors: challenges and recent advances

2013

Melatonin exerts many of its actions through the activation of two G protein-coupled receptors (GPCRs), named MT1 and MT2. So far, a number of different MT1 and MT2 receptor homology models, built either from the prototypic structure of rhodopsin or from recently solved X-ray structures of druggable GPCRs, have been proposed. These receptor models differ in the binding modes hypothesized for melatonin and melatonergic ligands, with distinct patterns of ligand-receptor interactions and putative bioactive conformations of ligands. The receptor models will be described, and they will be discussed in light of the available information from mutagenesis experiments and ligand-based pharmacophore …

Models MolecularProtein Conformationhomology modelingMolecular Sequence DataDruggabilityReviewComputational biologyLigandsBioinformaticsCatalysisInorganic Chemistrylcsh:ChemistryStructure-Activity Relationshipmelatonin receptorsAnimalsHumansAmino Acid SequenceHomology modelingmelatonin receptors; MT1; MT2; homology modeling; structure-activity relationships; docking; molecular dynamics simulationsPhysical and Theoretical ChemistryReceptorMolecular Biologylcsh:QH301-705.5SpectroscopyMelatoninG protein-coupled receptorBinding SitesSequence Homology Amino AcidbiologyReceptor Melatonin MT2Receptor Melatonin MT1MT1Organic ChemistryMT2structure-activity relationshipsGeneral Medicinemolecular dynamics simulationsComputer Science ApplicationsMelatonergiclcsh:Biology (General)lcsh:QD1-999Structural Homology ProteinDocking (molecular)RhodopsindockingMutagenesis Site-Directedbiology.proteinPharmacophore
researchProduct

A3 adenosine receptor: Homology modeling and 3D-QSAR studies

2012

Adenosine receptors (AR) belong to the superfamily of G-protein-coupled receptors (GPCRs). They are divided into four subtypes (A1, A2A, A2B, and A3) [1], and can be distinguished on the basis of their distinct molecular structures, distinct tissues distribution, and selectivity for adenosine analogs [2,3]. The hA3R, the most recently identified adenosine receptor, is involved in a variety of intracellular signaling pathways and physiological functions [4]. Expression of A3R was reported to be elevated in cancerous tissues [5], and A3 antagonists have been proposed for therapeutic treatments of cancer. The recent literature availability of crystal structure of hA2A adenosine receptor (PDB c…

Models MolecularQuantitative structure–activity relationshipReceptor Adenosine A2AAdenosine A3 Receptor AntagonistsQuantitative Structure-Activity RelationshipComputational biologyBiologyPharmacologyDrug DiscoveryMolecular dynamics simulationMaterials ChemistrymedicineHumansAmino Acid SequenceHomology modelingPhysical and Theoretical ChemistryReceptorA3 INHIBITORS HOMOLOGY MODELING 3D-QSARSpectroscopyG protein-coupled receptorA3 ReceptorBinding SitesTriazinesReceptor Adenosine A3Intracellular Signaling Peptides and ProteinsTriazolesA3 ADENOSINE RECEPTORComputer Graphics and Computer-Aided DesignAdenosine receptorAdenosineSettore CHIM/08 - Chimica FarmaceuticaPharmacophoresHomology modellingPharmacophoreProtein Bindingmedicine.drug
researchProduct

Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal …

2023

Pyruvate dehydrogenase kinases (PDKs) are serine/threonine kinases, that are directly involved in altered cancer cell metabolism, resulting in cancer aggressiveness and resistance. Dichloroacetic acid (DCA) is the first PDK inhibitor that has entered phase II clinical; however, several side effects associated with weak anticancer activity and excessive drug dose (100 mg/kg) have led to its limitation in clinical application. Building upon a molecular hybridization approach, a small library of 3-amino-1,2,4-triazine derivatives has been designed, synthesized, and characterized for their PDK inhibitory activity using in silico, in vitro, and in vivo assays. Biochemical screenings showed that …

PDK inhibitorsOrganic ChemistryKras-mutated pancreatic ductal adenocarcinomaGeneral Medicine3-amino-124-triazine derivativesantitumor agentsCatalysisbis-indole derivativesComputer Science ApplicationsInorganic Chemistryligand-based homology modelingPhysical and Theoretical ChemistryMolecular BiologySpectroscopyInternational Journal of Molecular Sciences
researchProduct

1,2,4-Amino-triazine derivatives as pyruvate dehydrogenase kinase inhibitors: Synthesis and pharmacological evaluation

2023

: Among the different hallmarks of cancer, deregulation of cellular metabolism turned out to be an essential mechanism in promoting cancer resistance and progression. The pyruvate dehydrogenase kinases (PDKs) are well known as key regulators in cells metabolic process and their activity was found to be overexpressed in different metabolic alerted types of cancer, including the high aggressive pancreatic ductal adenocarcinoma (PDAC). To date few PDK inhibitors have been reported, and the different molecules developed are characterized by structural chemical diversity. In an attempt to find novel classes of potential PDK inhibitors, the molecular hybridization approach, which combine two or m…

PharmacologyPDK inhibitors4-Amino-triazines1Organic ChemistryDrug Discovery2124-Amino-triazinesGeneral MedicineKRAS-mutated pancreatic cancerLigand-based homology modelingSettore CHIM/08 - Chimica Farmaceutica124-Amino-triazines; KRAS-mutated pancreatic cancer; Ligand-based homology modeling; PDK inhibitorsEuropean Journal of Medicinal Chemistry
researchProduct

Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in…

2023

Pancreatic ductal adenocarcinoma (PDAC) is one of the main aggressive types of cancer, characterized by late prognosis and drug resistance. Among the main factors sustaining PDAC progression, the alteration of cell metabolism has emerged to have a key role in PDAC cell proliferation, invasion, and resistance to standard chemotherapeutic agents. Taking into account all these factors and the urgency in evaluating novel options to treat PDAC, in the present work we reported the synthesis of a new series of indolyl-7-azaindolyl triazine compounds inspired by marine bis-indolyl alkaloids. We first assessed the ability of the new triazine compounds to inhibit the enzymatic activity of pyruvate de…

nortopsentin analoguespancreatic ductal adenocarcinoma (PDAC); nortopsentin analogues; antitumor activity; pyruvate dehydrogenase kinases (PDKs); cytotoxic activity; metabolic alterations; ligand-based homology modeling; KRASDrug Discoveryligand-based homology modelingKRASPharmaceutical Scienceantitumor activitymetabolic alterationspancreatic ductal adenocarcinoma (PDAC)Pharmacology Toxicology and Pharmaceutics (miscellaneous)cytotoxic activitypyruvate dehydrogenase kinases (PDKs)
researchProduct